Monopar director granted 1,284 stock options

Monopar Therapeutics director Nicole Sweeny received a grant of stock options, acquiring rights to 1,284 shares of common stock.

Rhea-AI Filing Summary

Monopar Therapeutics director Nicole Sweeny received a grant of stock options, acquiring rights to 1,284 shares of common stock. The options have an exercise price of $87.68 per share and expire on June 26, 2036.

The grant vests in two equal installments, with 50% vesting on September 30, 2026 and the remaining 50% vesting on December 31, 2026. Following this grant, Sweeny holds options on 1,284 shares directly. This is a compensation-related award rather than an open-market stock purchase or sale.

Insider Trade Summary

Grant/Award: 1,284 shares

Grant/Award 1 txn

Insider Sweeny Nicole

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	1,284	$0.00	$0.00

Holdings After Transaction: Stock Options — 1,284 contracts (Direct)

Footnotes (1)

1. F1. Options vest 50% on September 30, 2026, and 50% on December 31, 2026.

Key Figures

Options granted: 1,284 options Exercise price: $87.68 per share Shares underlying options: 1,284 shares +4 more

7 metrics

Options granted 1,284 options Stock options award to director on June 26, 2026

Exercise price $87.68 per share Strike price for the 1,284 stock options

Shares underlying options 1,284 shares Common stock underlying the options

Post-grant option holdings 1,284 options Total options beneficially owned after the transaction

Vesting schedule first tranche 50% on September 30, 2026 Half of options vest on this date

Vesting schedule second tranche 50% on December 31, 2026 Remaining options vest on this date

Option expiration date June 26, 2036 Last date to exercise this option grant

Key Terms

Stock Options, exercise price, expiration date, vesting, +1 more

5 terms

Stock Options financial

"security_title: "Stock Options""

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"conversion_or_exercise_price: "87.6800""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-26T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vesting financial

"Options vest 50% on September 30, 2026, and 50% on December 31, 2026."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Monopar Therapeutics (MNPR) director Nicole Sweeny report in this Form 4?

Director Nicole Sweeny reported receiving a grant of 1,284 stock options. These options give her the right to buy Monopar Therapeutics common stock at a fixed price, as part of her compensation, rather than reflecting an open-market trade.

How many Monopar Therapeutics stock options were granted to Nicole Sweeny and at what price?

Nicole Sweeny was granted 1,284 stock options with an exercise price of $87.68 per share. This means she can purchase up to 1,284 shares of Monopar Therapeutics common stock at $87.68, regardless of the market price, once the options vest.

When do Nicole Sweeny’s Monopar Therapeutics stock options vest?

The options vest in two equal tranches: 50% on September 30, 2026 and 50% on December 31, 2026. Vesting means she gradually earns the right to exercise the options and buy shares at the fixed exercise price.

When do Nicole Sweeny’s Monopar Therapeutics stock options expire?

The stock options granted to Nicole Sweeny expire on June 26, 2036. After that expiration date, any unexercised options will lapse, and she will no longer be able to purchase shares under this specific grant.

Did Nicole Sweeny buy or sell Monopar Therapeutics shares in the market?

This filing shows a grant of stock options as compensation, not a market trade. The transaction code is a grant or award, and the transaction price per option is listed as $0.00, indicating no open-market purchase or sale occurred.

How many Monopar Therapeutics options does Nicole Sweeny hold after this grant?

After this grant, Nicole Sweeny holds options on 1,284 shares of Monopar Therapeutics common stock directly. This figure reflects the total options from this award reported as beneficially owned following the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/30/2026 - 04:57 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sweeny Nicole

(Last) (First) (Middle)

1000 SKOKIE BLVD SUITE 350

(Street)

WILMETTE ILLINOIS 60091

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Monopar Therapeutics [ MNPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$87.68	06/26/2026		A		1,284		(1)	06/26/2036	Common Stock	1,284	$0	1,284	D

Explanation of Responses:

1. Options vest 50% on September 30, 2026, and 50% on December 31, 2026.

	/s/ Quan Vu, Attorney-in-fact	06/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)